// App-Quantinova.ai

2113 : Improvement in Key PsA Core Domains with Guselkumab Treatment in an Enriched Population of ACR20 Non-Responders at Week 24: Post Hoc Analysis of Two Phase 3 Studies

Researchers

Presenter

  • Dennis McGonagle

Principal Investigators

  • Derek Haaland

  • Philip Helliwell

  • A. Marilise Marrache

  • May Shawi

  • Emmanouil Rampakakis

  • Peter Nash

  • Fedra Irazoque Palazuelos

  • Arthur Kavanaugh

Medical Centers

  • School of Medicine, Griffith University, QLD, Australia, Brisbane, Australia

  • Angeles Mocel Hospital; Universidad Autónoma de México, Ciudad de México, Mexico

  • Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA

  • Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

  • University of California, San Diego, La Jolla, CA

  • The Waterside Clinic, Oro Medonte, ON, Canada

  • McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada

Locations

  • United Kingdom

  • Canada

  • United States

  • Australia

  • Mexico

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

  • Musculoskeletal

Disease

  • Dactylitis

  • Psoriasis

Biomarkers

  • C reactive protein

  • Albumin/creatinine

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved